PRKAA2 and chronic myelogenous leukemia, BCR-ABL1 positive: In Chronic Myeloid Leukemia (CML), BCL-ABL transformed cells exhibit overly expressed mTOR activity by which activating AMPK may provide therapeutic advantages [61].